Yıl 2018, Cilt 4, Sayı 4, Sayfalar 320 - 325 2018-10-04

Effects of a single dose 20 mg tadalafil on resistive index value of prostate zones

Tayfun Şahinkanat [1] , Erkan Efe [2] , Hasan Çetin Ekerbiçer [3] , Faruk Küçükdurmaz [4]

65 163

Objectives: Although there are several studies addressing the efficacy of phosphodiesterase type 5 inhibitors for the management of benign prostatic hyperplasia-lower urinary tract symptoms (BPH-LUTS), unfortunately, there is a lack of high evidence data to support their effect at the prostate level. The existing studies suggested that resistive index (RI) could be used as a hemodynamic parameter to measure the severity of benign prostatic hyperplasia and intraprostatic pressure or bladder outlet obstruction. The aim of this study was to evaluate the effect of a single dose 20 mg tadalafil on resistive index value in prostate zones to evaluate the mechanism of action of phosphodiesterase type 5-inhibitors at the prostate level.

Methods: Twenty consecutive patients aged between 54-67 years with BPH-LUTS [International Prostate Symptom Score ≥ 12] and erectile dysfunction [five-item International Index of Erectile Function (IIEF) questionnaire < 22] underwent RI measurement in prostate transitional zone (TZ) and peripheral zone (PZ) using transrectal power Doppler ultrasonography baseline and within 16 hours after the administration of 20 mg tadalafil. The primary study end point is the change in prostate TZ RI values.

Results: The mean baseline total prostate scores and peak urinary flow were 16.2 ± 4.34 (range: 12-26) and 10.45 ml/s (range: 7-13 ml/s), respectively. The mean baseline total IIEF was 12.8 ± 4.22 (range: 6-20). The mean TZ RI at baseline and after tadalafil administration were 0.4985 and 0.5497, respectively (p = 0.232). No statistically significant differences for RI changes between baseline and after the administration of a single dose 20 mg tadalafil were observed in the prostatic zones.

Conclusion: A single dose 20 mg tadalafil showed no impact on prostate TZ RI. 

tadalafil, prostate, phosphodiesterase type 5 inhibitors, resistive index, erectile dysfunction
  • [1] Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008;180:1228-34.
  • [2] Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53:1236-44.
  • [3] McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177:1401-7.
  • [4] McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized, double-blind trial. J Urol 2007;177:1071-7.
  • [5] Roehrborn CG, Kaminetsky JC, Auerbach SM, Montelongo RM, Elion-Mboussa A, Viktrup L. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int 2010;105:502-7.
  • [6] Tinel H, Stelte-Ludwig B, Hutter J, Sandner P. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006;98:1259-63.
  • [7] Waldkirch ES, Uckert S, Langnase K Richter K, Jonas U, Wolf G, et al. Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur Urol 2007;52:495-501.
  • [8] Grimsley SJ, Khan MH, Jones GE. Mechanism of phosphodiesterase 5 inhibitor relief of prostatitis symptoms. Med Hypotheses 2007;69:25-6.
  • [9] Yencilek E, Koyuncu H, Arslan D, Bastug Y. The measurement of the prostatic resistive index is a reliable ultrasonographic tool to stratify symptoms of patients with benign prosthatic hyperplasia. Med Ultrason 2014;16:208-13.
  • [10] Zhang X, Li G, Wei X, Mo X, Hu L, Zha Y, et al. Resistive index of prostate capsular arteries: a newly identified parameter to diagnose and assess bladder outlet obstruction in patients with benign prostatic hyperplasia. J Urol 2012;188:881-7.
  • [11] Kojima M, Ochiai A, Naya Y, Okihara K, Ukimura O, Miki T. Doppler resistive index in benign prostatic hyperplasia: correlation with ultrasonic appearance of the prostate and infravesical obstruction. Eur Urol 2000;37:436-42.
  • [12] Tsuru N, Kurita Y, Masuda H, Suzuki K, Fujita K. Role of Doppler ultrasound and resistive index in benign prostatic hypertrophy. Int J Urol 2002;9:427-30.
  • [13] Pinggera GM, Frauscher F, Paduch DA, Bolyakov A, Efros M, Kaminetsky J, et al. Effect of tadalafil once daily on prostate blood flow and perfusion in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, double-blind, multicenter, placebo-controlled trial. Urology 2014;84: 412-20.
  • [14] Bertolotto M, Trincia E, Zappetti R, Bernich R, Savoca G, Cova MA. Effect of tadalafil on prostate haemodynamics: preliminary evaluation with contrastenhanced US. Radiol Med 2009;114:1106-14.
  • [15] Haaga JR, Exner A, Fei B, Seftel A. Semiquantitative imaging measurement of baseline and vasomodulated normal prostatic blood flow using sildenafil. Int J Impot Res 2007;19:110-3.
  • [16] Berger AP, Deibl M, Leonhartsberger N, Bektic J, Horninger W, Fritsche G, et al. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int 2005;96:1073-8.
  • [17] Kojima M, Watanabe H, Watanabe M, Okihara K, Naya Y, Ukimura O. Preliminary results of power Doppler imaging in benign prostatic hyperplasia. Ultrasound Med Biol 1997;23:1305-9.
  • [18] Abdelwahab O, El-Barky E, Khalil MM, Kamar A. Evaluation of the resistive index of prostatic blood flow in benign prostatic hyperplasia. Int Braz J Urol 2012;38:250-5.
  • [19] Özden C, Günay I, Deren T, Bulut S, Koparal S, Memiş A. Effect of doxazosin on prostatic resistive index in patients with benign prostatic hyperplasia. Fırat Tıp Dergisi 2009;14:171-4.
  • [20] Ozden C, Gunay I, Deren T, Bulut S, Ozdal OL, Koparal S, et al. Effect of transurethral resection of prostate on prostatic resistive index. Urol Int 2010;84:191-3.
  • [21] Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combinationwith α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61:994-1003.
Birincil Dil en
Konular Sağlık Bilimleri
Dergi Bölümü Original Article
Yazarlar

Yazar: Tayfun Şahinkanat
Kurum: Department of Urology, Kahramanmaraş Sütçü İmam University School of Medicine, Kahramanmaraş
Ülke: Turkey


Yazar: Erkan Efe
Kurum: Department of Urology, Kahramanmaraş Sütçü İmam University School of Medicine, Kahramanmaraş
Ülke: Turkey


Yazar: Hasan Çetin Ekerbiçer
Kurum: Department of Public Health, Sakarya University School of Medicine, Sakarya
Ülke: Turkey


Orcid: 0000-0002-7946-6916
Yazar: Faruk Küçükdurmaz
Kurum: Department of Urology, Kahramanmaraş Sütçü İmam University School of Medicine, Kahramanmaraş
Ülke: Turkey


Bibtex @araştırma makalesi { eurj349721, journal = {The European Research Journal}, issn = {}, eissn = {2149-3189}, address = {Sağlık Araştırmaları ve Stratejileri Derneği}, year = {2018}, volume = {4}, pages = {320 - 325}, doi = {10.18621/eurj.349721}, title = {Effects of a single dose 20 mg tadalafil on resistive index value of prostate zones}, key = {cite}, author = {Şahinkanat, Tayfun and Ekerbiçer, Hasan Çetin and Küçükdurmaz, Faruk and Efe, Erkan} }
APA Şahinkanat, T , Efe, E , Ekerbiçer, H , Küçükdurmaz, F . (2018). Effects of a single dose 20 mg tadalafil on resistive index value of prostate zones. The European Research Journal, 4 (4), 320-325. DOI: 10.18621/eurj.349721
MLA Şahinkanat, T , Efe, E , Ekerbiçer, H , Küçükdurmaz, F . "Effects of a single dose 20 mg tadalafil on resistive index value of prostate zones". The European Research Journal 4 (2018): 320-325 <http://dergipark.gov.tr/eurj/issue/32988/349721>
Chicago Şahinkanat, T , Efe, E , Ekerbiçer, H , Küçükdurmaz, F . "Effects of a single dose 20 mg tadalafil on resistive index value of prostate zones". The European Research Journal 4 (2018): 320-325
RIS TY - JOUR T1 - Effects of a single dose 20 mg tadalafil on resistive index value of prostate zones AU - Tayfun Şahinkanat , Erkan Efe , Hasan Çetin Ekerbiçer , Faruk Küçükdurmaz Y1 - 2018 PY - 2018 N1 - doi: 10.18621/eurj.349721 DO - 10.18621/eurj.349721 T2 - The European Research Journal JF - Journal JO - JOR SP - 320 EP - 325 VL - 4 IS - 4 SN - -2149-3189 M3 - doi: 10.18621/eurj.349721 UR - http://dx.doi.org/10.18621/eurj.349721 Y2 - 2018 ER -
EndNote %0 The European Research Journal Effects of a single dose 20 mg tadalafil on resistive index value of prostate zones %A Tayfun Şahinkanat , Erkan Efe , Hasan Çetin Ekerbiçer , Faruk Küçükdurmaz %T Effects of a single dose 20 mg tadalafil on resistive index value of prostate zones %D 2018 %J The European Research Journal %P -2149-3189 %V 4 %N 4 %R doi: 10.18621/eurj.349721 %U 10.18621/eurj.349721
ISNAD Şahinkanat, Tayfun , Efe, Erkan , Ekerbiçer, Hasan Çetin , Küçükdurmaz, Faruk . "Effects of a single dose 20 mg tadalafil on resistive index value of prostate zones". The European Research Journal 4 / 4 (Ekim 2018): 320-325. http://dx.doi.org/10.18621/eurj.349721